Expired CME Article

Management of Chronic Kidney Disease: What is the Evidence?

Authors: Godela Brosnahan, MD, Mony Fraer, MD

Abstract

Chronic kidney disease (CKD) is a strong risk factor for cardiovascular events and death. Hypertension, dyslipidemia, anemia, vascular calcification, and secondary hyperparathyroidism have all been implicated in the pathogenesis of cardiovascular disease associated with CKD. Numerous trials have been performed assessing the effects of modifying these risk factors on cardiovascular events and on the progression to end-stage renal disease. Many guidelines have been issued. In this article we review the guidelines and the strength of evidence supporting them. Specifically, we discuss blood pressure goals for patients with CKD, the role of renin-angiotensin system blocking agents for blood pressure control and proteinuria reduction, and the evidence for treatment recommendations of dyslipidemia. We review the trials addressing risks and benefits of different hemoglobin targets for treatment of anemia with erythropoietin. The use of phosphate-binding drugs to prevent and treat secondary hyperparathyroidism is likely beneficial, but few data support the use of vitamin D compounds. Supplementation with sodium bicarbonate may be an inexpensive treatment to retard progression to end-stage renal disease. The article concludes with a discussion of the case vignette presented in the previous article.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Coresh J, Wei GL, McQuillan G. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health And Nutrition Examination Survey (1988–1994). Arch Intern Med 2001;161:1207–1216. (Cross-sectional study; 16,589 subjects)
 
2.Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005;45:994–1001. (Cross-sectional study; 232 subjects)
 
3.Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998;13:3091–3095. (Retrospective cross-sectional study; 201 subjects)
 
4.Ruilope LM, Salvetti A, Jamerson K. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218–225. (Randomized placebo-controlled trial;18,790 subjects)
 
5.Shulman NB, Ford CE, Hall WD. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The hypertension detection and follow-up program cooperative group. Hypertension 1989;13:I80–I93. (Randomized, controlled trial; 10,940 subjects)
 
6.Bakris GL, Weir MR, Shanifar S, et al; for the RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555–1565. (Randomized, placebo-controlled trial; 1,513 subjects)
 
7.Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease study. Ann Intern Med 1995;123:754–762. (Randomized 2 × 2 factorial trial; 840 subjects)
 
8.Pahor M, Shorr RI, Somes GW. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the Systolic Hypertension in the Elderly Program. Arch Intern Med 1998;158:1340–1345. (Randomized, double-blind, placebo-controlled trial; 4,336 subjects)
 
9.Sarnak MJ, Levey AS, Schoolwerth AC. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154–2169. (AHA scientific statement)
 
10.Chobanian AV, Bakris GL, Black HR. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–1252. (Clinical practice guidelines)
 
11.Jafar TH, Stark PC, Schmid CH. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003;139:244–252. (Meta-analysis of 11 randomized, controlled trials; 1,860 subjects)
 
12.Deferrari G, Ravera M, Berruti V. Treatment of diabetic nephropathy in its early stages. Diabetes Metab Research Rev 2003;19:101–114. (Review)
 
13.Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005;16:3027–3037. (Randomized, double-blind, placebo-controlled trial: 1,590 subjects)
 
14.Klahr S, Levey AS, Beck GJ. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease study group. N Engl J Med 1994;330:877–884. (Randomized 2 × 2 factorial trial; 1840 subjects)
 
15.Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease study. Kidney Int 1997;51:1908–1919. (Systematic analysis of a randomized controlled trial; 840 subjects)
 
16.Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993;329:1456–1462. (Prospective randomized trial; 409 subjects)
 
17.Mascjio G, Alberti O, Janin G, et al. Effect of angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939–945. (Prospective, double-blind, randomized study; 583 subjects)
 
18.The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863. (Randomized placebo-controlled trial; 352 subjects)
 
19.Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359–364. (Randomized, double-blind, placebo-controlled trial; 186 subjects)
 
20.Brenner BM, Cooper ME, de Zeeuw D, et al; for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869. (Randomized, double-blind trial; 1513 subjects)
 
21.Parving HH, Lehnert H, Brochner-Mortensen J, et al; for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878. (Randomized, double-blind, placebo-controlled trial; 590 subjects)
 
22.Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793–797. (Prospective study of 40 patients)
 
23.Arici M, Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 2009;53:332–345. (Review)
 
24.Catapano F, Chiodini P, DeNicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am J Kidney Dis 2008;52:475–485. (Meta-analysis of 13 randomized controlled trials; 425 subjects)
 
25.Mann JFE, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–553. (Randomized, double-blind trial; 25,620 subjects)
 
26.Berns JS. Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? Am J Kidney Dis 2009;53:192–196. (Review)
 
27.Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682–1685. (Cohort study; 7 subjects)
 
28.Rose BD. Diuretics. Kidney Int 1991;39:336–352. (Review)
 
29.Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002;13:798–805. (Review)
 
30.Fliser D, Schroter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46:482–488. (Single-blind, randomized, placebo-controlled crossover study; 10 subjects)
 
31.Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963–1974. (Meta-analysis; 1124 subjects)
 
32.Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:287. (Double-blind, placebo-controlled trial; 1,647 subjects)
 
33.Habib AN, Baird BC, Leypoldt JK, et al. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006;21:2881–2892. (Retrospective cohort study; 1053 patients)
 
34.Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293–303. (Retrospective cohort study; 15,859 patients)
 
35.Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–248. (Randomized placebo-controlled trial; 1255 patients)
 
36.Fellstrom BC, Jardine AG, Schmieder RE, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395–1407. (Randomized, double-blind, placebo-controlled trial; 2776 patients)
 
37.Wanner C. Statin effects in CKD: is there a “point of no return”? Am J Kidney Dis 2009;53:723–725. (Editorial comment)
 
38.Tonelli M, Moyé L, Sacks FM, et al; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98–104. (Post-hoc subgroup analysis of a randomized placebo-controlled trial; 1711 patients with CKD)
 
39.Tonelli M, Isles C, Curhan G, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557–1563. (Post-hoc subgroup analysis of 3 randomized placebo-controlled trials; 4,491 patients with CKD)
 
40.Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005;16:3748–3754. (Post-hoc analysis of 3 randomized placebo-controlled trials; 19,737 patients)
 
41.Chonchol M, Cook T, Kjekshus J, et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 2007;49:373–382. (Post-hoc subgroup analysis of a randomized placebo-controlled trial; 2,314 patients with CKD)
 
42.Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (treating to new targets) study. J Am Coll Cardiol 2008;51:1448–1454. (Post-hoc subgroup analysis of a randomized trial of atorvastatin 80 mg/day versus 10 mg/day; 3,107 patients with CKD)
 
43.Stegmayr BG, Brannstrom M, Bucht S, et al. Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study. Scand J Urol Nephrol 2005;39:489–497. (Randomized, placebo-controlled trial; 143 patients)
 
44.Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898–2908. (Experimental study in 40 rats)
 
45.Tonelli M, Moyé L, Sacks FM, et al; for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605–1613. (Post-hoc subgroup analysis of a randomized placebo-controlled trial; 690 patients with CKD)
 
46.Shepherd J, Kastelein JJP, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131–1139. (Post-hoc analysis of a randomized placebo-controlled trial; 9,656 patients with complete renal data)
 
47.Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645–651. (Meta-analysis of 50 randomized, controlled trials; 30,144 patients)
 
48.National Kidney Foundation: K/DOQ Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003;41(suppl 3):S1–S91. (Clinical practice guidelines)
 
49.Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497. (Clinical practice guidelines)
 
50.Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008;51:2375–2384. (Review)
 
51.Fassett RG, Ball MJ, Robertson IK, et al. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol 2008;9:4–9. (Randomized, placebo-controlled trial; ongoing, goal of 200 patients)
 
52.Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int 2003;63(suppl 84):S207–S210. (Randomized controlled trial; goal of 9,000 patients)
 
53.KDOQI: National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(suppl 3):S16–S85. (Clinical practice guidelines)
 
54.Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1– ii47. (Clinical practice guidelines)
 
55.Winearls CG, Pippard MJ, Downing MR, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;328:1175–1178. (Prospective interventional trial; 10 patients)
 
56.Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined Phase I and II clinical trial. N Engl J Med 1987;316:73–78. (Prospective interventional trial; 25 patients)
 
57.Eschbach JW, Kelly MR, Haley R, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158–163. (Randomized controlled trial; 17 patients)
 
58.Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548–554. (Randomized open-label trial; 83 patients)
 
59.Muirhead N, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995;26(suppl 1):S1–S24. (Review and guidelines)
 
60.The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18:50–59. (Randomized controlled trial; 117 patients)
 
61.Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777–784. (Randomized open-label trial; 83 patients)
 
62.Jones M, Ibels L, Schenkel B, et al. Impact of epoietin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004;65:757–767. (Meta-analysis of 5 randomized controlled and 11 uncontrolled trials; 25,080 patients)
63.Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin < 10 g/dL. Kidney Int 2005;68:788–795. (Open-label interventional trial; 40 patients and 61 controls)
 
64.Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250–256. (Prospective study; 9 patients)
 
65.Lu WX, Jones-Burton C, Zhan M, et al. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005;101:c79–c86. (Retrospective cohort study; 15,807 patients)
 
66.Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560–564. (Retrospective cohort study; 853 patients)
 
67.Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799–811. (Randomized controlled trial; 172 patients)
 
68.Strippoli GF, Craig JC, Manno C, et al. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004;15:3154–3165. (Meta-analysis of 19 randomized controlled trials; 2696 patients)
 
69.Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584–590. (Randomized controlled trial; 618 patients)
70.Singh AK, Szczech L, Tang K, et al. Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med 2006:2085–2098. (Randomized controlled trial; 1432 patients)
 
71.Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–2084. (Randomized controlled trial; 603 patients)
 
72.KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471–530. (Clinical practice guidelines)
 
73.Atsumi K, Kushida K, Yamazaki K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287–293. (Cross-sectional study; 187 subjects)
 
74.Ensrud KE, Lui L-Y, Taylor BC, et al. Renal function and risk of hip and vertebral fractures among older women. Arch Intern Med 2007;167:133–139. (Case-control study; 299 subjects)
 
75.Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520–528. (Retrospective cohort study; 3490 patients)
 
76.Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607–617. (Retrospective cohort study; 6407 patients)
 
77.Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138. (Retrospective cohort study; 12,833 patients)
 
78.Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009;20:381–387. (Cross-sectional study; 439 subjects)
 
79.Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009;20:397–404. (Prospective observational study; 3015 subjects)
 
80.Qunibi WY. The CARE study and cardiovascular calcification. Managed Care 2006;15:1–5. (Review)
 
81.Palmer SC, McGregor DO, Macaskill P, et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007;147:840–853. (Meta-analysis of 76 trials; 3667 patients)
 
82.Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med 2007;147:880–881. (Editorial comment)
 
83.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1–S201. (Clinical practice guidelines)
 
84.de Brito-Ashurst I, Varagunam M, Raftery MJ, et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009;20:2075–2084. (Randomized trial; 134 patients)
 
85.Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbopoietin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032